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Retention and clinical response 
to abatacept in patients with 
rheumatoid arthritis: 
an Italian perspective
Sirs,
Country differences are important con-
siderations when assessing the impact of 
patient characteristics on clinical response 
to anti-rheumatic drugs (1). In Italy, the 
proportion of people aged ≥65 years is one 
of the highest in Europe (2) and is likely to 
be accompanied by an increased burden of 
rheumatoid arthritis (RA) (3). Abatacept is 
approved as a first-line biologic after dis-
ease-modifying anti-rheumatic drug failure 
in Italy (4). Lower abatacept retention rates 
have been reported in European countries 
with easier access to biologics (1). However, 
Italian patients were among the least likely 
to discontinue abatacept in the large, 2-year, 
non-interventional, international ACTION 
cohort study (NCT02109666) in which pre-
scribing guidelines and reimbursement were 
uniform across participating countries (5).
To provide a local perspective on the im-
pact of patient characteristics on retention 
rate and clinical response to abatacept, we 
analysed the 12-month data in the Italian 
cohort of ACTION (n=441). Patients ≥18 
years old with moderate-to-severe RA were 
enrolled prospectively at initiation of intra-
venous abatacept or retrospectively within 
3 months of the first abatacept dose accord-
ing to local requirements (6). Baseline rheu-
matoid factor (RF)/anti-citrullinated protein 
antibody (ACPA) serostatus was available for 
371/441 patients: 183/371 (49%) were dou-
ble RF/ACPA-positive; 112/371 (30%) were 
single RF- or ACPA-positive; and 76/371 
(20%) were double RF/ACPA-negative. 
Baseline body mass index (BMI) was report-
ed in 435/441 patients: 224/435 (51%) were 
underweight / normal; 130/435 (30%) were 
overweight; and 81/435 (19%) were obese. 
Baseline seropositivity had a significant 
impact on the crude abatacept retention 
rate at 12 months (log-rank test: p=0.043; 
Fig. 1a). Crude abatacept retention rates 
(95% confidence intervals [CIs]) at 12 
months in the Italian cohort were higher in 
single RF- or ACPA-positive or double RF/
ACPA-positive patients (85.1% [76.9, 90.6] 
and 80.2% [73.6, 85.4], respectively) than in 
double RF/ACPA-negative patients (70.3% 
[58.5, 79.4]). Over 12 months, abatacept 
discontinuation rates due to inefficacy were 
numerically lower with baseline seroposi-
tivity versus seronegativity: 25/35, 14/20 
and 18/23 patients in the double RF/AC-
PA-positive, single RF- or ACPA-positive 
and double RF/ACPA-negative subgroups, 
respectively. RF/ACPA positivity on abata-
cept initiation was associated with a trend 
towards improved good / moderate   EULAR 
response rates (95% CIs) based on Disease 
Activity Score in 28 joints (erythrocyte 
sedimentation rate, otherwise C-reactive 
protein) at 12 months: 83.7% (76.5, 90.8), 
73.1% (63.2, 82.9) and 65.9% (52.4, 79.5) in 
the double RF/ACPA-positive, single RF- or 
ACPA-positive and double RF/ACPA-nega-
tive subgroups, respectively (Fisher’s exact 
test: p=0.056).
Crude abatacept retention rates (95% CIs) 
at 12 months were similar across BMI 
subgroups: 75.5% (69.2, 80.7), 82.1% 
(74.1, 87.8) and 79.4% (68.6, 86.9) in 
the underweight/normal, overweight and 
obese subgroups, respectively (log-rank 
test: p=0.629; Fig. 1b). Over 12 months, 
abatacept discontinuation rates due to in-
efficacy were numerically higher in the 
obese versus the underweight / normal and 
overweight subgroups at 15/17, 37/53 and 
18/25 patients, respectively, and were asso-
ciated with a higher rate of co-morbidity. 
Discontinuation rates due to intolerance 
were lower in the obese versus the under-
weight / normal and overweight subgroups: 
2/17, 9/53 and 5/25 patients, respectively. 
There were no significant differences in 
good / moderate EULAR response rates 
(95% CIs) at 12 months across baseline 
BMI subgroups: 76.5% (68.8, 84.1), 75.9% 
(66.7, 85.1) and 73.3% (60.4, 86.3) in the 
underweight / normal, overweight and obese 
subgroups, respectively (Fisher’s exact test: 
p=0.854).
Our findings for the Italian cohort of 
ACTION demonstrate improved abatacept 
retention and clinical response with RF/
ACPA positivity and are consistent with 
2-year results for the overall international 
population (5), and for a European RA 
registry analysis (7). Baseline BMI did 
not impact abatacept retention or clinical 
response, also consistent with the overall 
ACTION study and an international regis-
try analysis (5, 8). These findings highlight 
the relevance of abatacept real-world data 
in different patient subpopulations to the 
management of RA in Italy.
Fig. 1. Crude retention rate of abatacept by a) RF/ACPA serostatus and b) body mass index, in the Italian cohort 
of ACTION. ACPA: anti-citrullinated protein antibody; CI: confidence interval; pt: patient; RF: rheumatoid factor.
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